GE HealthCare announced CE Mark approval for its MINItrace Magni system and expanded its PETtrace platform to support Copper-64.
The company said MINItrace™ Magni has received CE Mark approval and that Copper-64 extends the PETtrace™ Solid Target Platform beyond Gallium-68. The announcement does not include launch timing, sales expectations or details on the commercial impact of either development.
Investor takeaway: The announcement confirms a regulatory milestone for MINItrace Magni and an expansion of the PETtrace platform. It does not quantify their expected contribution to the business.
Advertisement
GE HealthCare Technologies Inc.
GEHC.US
GEHC.US
GE HealthCare Technologies Inc.
WealthAwesomeMarket cap
$31.78B
P/E
15.8x
Div. yield
0.20%
Div. / share
$0.14
52W high
$89.64
52W low
$58.72
1W change
+9.55%
Beta
0.85
Analyst Price Targets
Based on 21 analysts covering GEHC · as of Oct 14, 2026
Wall Street analysts forecast GEHC stock price to rise 17.6% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$82.70
+17.6% Upside
Previously C$82.90 on Oct 12, 2026
Current Price
C$70.35
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GEHC's historical volatility
30-Day Vol
24.8%
Annualized
90-Day Vol
35.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$84.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$74.66 | C$68.55 – C$81.33 |
| 60 trading days | C$79.24 | C$70.22 – C$89.43 |
| 90 trading days | C$84.10 | C$72.53 – C$97.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
GE HealthCare closed at US$70.35
Shares rose 2.75% on the day. Trading volume was 3,745,665 shares, or 0.96 times the 20-day average.
Bull case
The announcement marks a regulatory milestone for MINItrace Magni and expands the range of isotopes supported by the PETtrace Solid Target Platform.
Bear case
The announcement provides no details on demand, revenue, rollout timing or financial impact. On its own, it does not show how much these developments could affect results.
What happened: MINItrace Magni achieves CE Mark
Advertisement
The October 15 headline reports that GE HealthCare's MINItrace™ Magni received CE Mark approval. It also says Copper-64 expands the PETtrace™ Solid Target Platform beyond Gallium-68. The news item does not explain the approval's scope, name the markets where the system will be available or give a launch date. Follow the company on the GE HealthCare stock page.
What the numbers show: shares close at US$70.35
GE HealthCare shares closed at US$70.35, up 2.75% for the day and 9.55% over the week. Volume was 3,745,665 shares, compared with a 20-day average of 3,888,530, or 0.96 times the average. These figures do not show that the announcement drove the share-price move. The close was 38% of the stated 52-week range, from US$58.72 to US$89.64. See the GEHC stock page for more quote and company information.
What to watch next: commercial details are not yet supplied
The announcement does not say when MINItrace Magni could reach customers, how Copper-64 will be added to PETtrace offerings, or whether either development is expected to affect revenue or earnings. Those details would help investors assess the business impact. For now, the disclosed developments are the CE Mark milestone and the platform's expansion beyond Gallium-68.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
